756 Stock Overview
Shandong Xinhua Pharmaceutical Company Limited, through its subsidiaries, develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 4/6 |
Shandong Xinhua Pharmaceutical Company Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$16.15 |
52 Week High | HK$26.85 |
52 Week Low | HK$13.45 |
Beta | -0.011 |
1 Month Change | -3.47% |
3 Month Change | 8.53% |
1 Year Change | -38.36% |
3 Year Change | 76.50% |
5 Year Change | 121.23% |
Change since IPO | 65.45% |
Recent News & Updates
Recent updates
Shareholder Returns
756 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | 3.3% | 4.2% | 2.9% |
1Y | -38.4% | -12.8% | -13.2% |
Return vs Industry: 000756 underperformed the CN Pharmaceuticals industry which returned -11% over the past year.
Return vs Market: 000756 underperformed the CN Market which returned -13.1% over the past year.
Price Volatility
756 volatility | |
---|---|
756 Average Weekly Movement | 5.4% |
Pharmaceuticals Industry Average Movement | 7.3% |
Market Average Movement | 8.5% |
10% most volatile stocks in CN Market | 12.5% |
10% least volatile stocks in CN Market | 5.1% |
Stable Share Price: 000756 has not had significant price volatility in the past 3 months.
Volatility Over Time: 000756's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1943 | 7,104 | n/a | www.xhzy.com |
Shandong Xinhua Pharmaceutical Company Limited, through its subsidiaries, develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic and analgesic drugs; cardiovascular and cerebrovascular drugs; anti-infective drugs and central nervous drugs; and other drugs. It engages in the development of real estate business.
Shandong Xinhua Pharmaceutical Company Limited Fundamentals Summary
756 fundamental statistics | |
---|---|
Market cap | CN¥8.87b |
Earnings (TTM) | CN¥486.79m |
Revenue (TTM) | CN¥7.94b |
7.2x
P/E Ratio0.4x
P/S RatioIs 756 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
756 income statement (TTM) | |
---|---|
Revenue | CN¥7.94b |
Cost of Revenue | CN¥5.76b |
Gross Profit | CN¥2.17b |
Other Expenses | CN¥1.69b |
Earnings | CN¥486.79m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.71 |
Gross Margin | 27.37% |
Net Profit Margin | 6.13% |
Debt/Equity Ratio | 26.3% |
How did 756 perform over the long term?
See historical performance and comparison